Jun 2026 (Q2 FY26) — Aug 11, 2026
Bicara Therapeutics Q2 FY26 — Leadership Transition and Pivotal Study Progress
Read the full callBicara Therapeutics (BCAX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Bicara Therapeutics earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -55.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$16.78 −4.77% · −$0.84
Performance −10.8% 1Y
1Y: $18.81 on 15 Oct 2025 → $16.78. High $30.4 (7 Jul 2026), low $13.93 (10 Nov 2025).
- Previous close
- $17.62
- 52-week range
- $13.93 – $30.4
- One year
- −10.17%
Overview
- Symbol
- BCAX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Bicara Therapeutics earnings calls (BCAX)
Financials
What the filings say
Net profit, year on year: −102% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -21 | -27 | -42 | -32 | -41 | -41 | -60 | -60 |
| Other income | 3 | 6 | 5 | 5 | 4 | 4 | 4 | 5 |
| Profit before tax | -17 | -21 | -37 | -27 | -36 | -37 | -56 | -55 |
| Tax rate | 0.0% | −0.9% | −0.2% | −0.2% | −0.1% | −0.1% | −0.1% | −0.1% |
| Net profit | -17 | -21 | -37 | -27 | -36 | -37 | -56 | -55 |
| EPS ($ per share) | -1.60 | — | -0.68 | -0.50 | -0.67 | — | -0.93 | -0.82 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | 0 | 0 | 0 |
| Reserves | -153 | -221 | -359 |
| Total liabilities | 15 | 18 | 30 |
| Fixed assets | 0 | 0 | 0 |
| Investments | — | 0 | 318 |
| Total assets | 234 | 510 | 431 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -46 | -75 | -107 |
| Cash from investing | -1 | -0 | -318 |
| Cash from financing | 272 | 334 | 32 |
| Net cash flow | 226 | 259 | -393 |
| Capital expenditure | -1 | -0 | -0 |
| Free cash flow | -46 | -75 | -107 |
Insider filings
105 filings between Nov 21, 2025 and Sep 8, 2026.
Open market
decisions to buy or sellPurchases
$4.80M
1 purchase by 1 insider
Sales
$9.91M
57 sales by 4 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 47
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $4.80M | — | Feb 26, 2026 |
| Cohlhepp Ryan | — | $3.46M | Sep 8, 2026 |
| Mazumdar Claire | — | $3.14M | Aug 10, 2026 |
| Hyep Ivan | — | $2.57M | Aug 10, 2026 |
| Raben David | — | $740.8K | Apr 27, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Cohlhepp Ryan President, COO & Interim CEO | Option exercise 10b5-1 plan | 17,500 | $66.3K |
| Sep 8, 2026 | Cohlhepp Ryan President, COO & Interim CEO | Sale 10b5-1 plan | 3,442 | $80.7K |
| Sep 8, 2026 | Cohlhepp Ryan President, COO & Interim CEO | Sale 10b5-1 plan | 14,058 | $320.1K |
| Aug 10, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 10,000 | $37.9K |
| Aug 10, 2026 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 plan | 18,750 | $71.1K |
| Aug 10, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 10,000 | $279.8K |
| Aug 10, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 12,500 | $349.6K |
| Aug 10, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 18,750 | $524.5K |
| Aug 10, 2026 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 plan | 12,500 | $47.4K |
| Jul 10, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 9,972 | $283.4K |
| Jul 10, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 10,000 | $37.9K |
| Jul 10, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 28 | $831 |
| Jul 9, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 536 | $15.5K |
| Jul 8, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 22,833 | $656.7K |
| Jul 8, 2026 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 plan | 18,750 | $71.1K |
| Jul 8, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 830 | $25.2K |
| Jul 8, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 4,413 | $131.6K |
| Jul 8, 2026 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 plan | 12,500 | $47.4K |
| Jul 8, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 4,306 | $128.3K |
| Jul 8, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 1,075 | $32.6K |
| Jul 8, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 22,757 | $650.9K |
| May 21, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 9,200 | $187.9K |
| May 21, 2026 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 plan | 9,200 | $34.9K |
| May 18, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 2,978 | $60.6K |
| May 18, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 12,022 | $240.0K |
| May 18, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 15,000 | $56.8K |
| May 15, 2026 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 plan | 8,000 | $30.3K |
| May 15, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 4,500 | $91.3K |
| May 15, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 8,000 | $162.3K |
| Apr 27, 2026 | Raben David Chief Medical Officer | Sale 10b5-1 plan | 5,500 | $125.8K |
| Apr 27, 2026 | Raben David Chief Medical Officer | Option exercise 10b5-1 plan | 5,500 | $20.8K |
| Apr 21, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 9,200 | $211.6K |
| Apr 21, 2026 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 plan | 9,200 | $34.9K |
| Apr 20, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 15,000 | $354.1K |
| Apr 20, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 15,000 | $56.8K |
| Apr 16, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 7,454 | $28.2K |
| Apr 16, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 8,226 | $36.5K |
| Apr 16, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 7,080 | $38.6K |
| Apr 15, 2026 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 plan | 8,000 | $30.3K |
| Apr 15, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 4,500 | $103.5K |
| Apr 15, 2026 | Cohlhepp Ryan President and COO | Sale 10b5-1 plan | 8,000 | $184.1K |
| Mar 25, 2026 | Raben David Chief Medical Officer | Sale 10b5-1 plan | 5,500 | $104.2K |
| Mar 25, 2026 | Raben David Chief Medical Officer | Option exercise 10b5-1 plan | 5,500 | $20.8K |
| Mar 23, 2026 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 plan | 9,200 | $34.9K |
| Mar 23, 2026 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 plan | 9,200 | $170.3K |
| Mar 20, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 1,596 | $30.2K |
| Mar 20, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 1,596 | $6.0K |
| Mar 19, 2026 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 plan | 6,905 | $129.7K |
| Mar 19, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 6,905 | $26.2K |
| Mar 18, 2026 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 plan | 6,499 | $24.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Bicara Therapeutics Inc.
Free account. Everything above stays public.
Write why you follow Bicara Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading